Quantification Supports Amyloid PET Visual Assessment of Challenging Cases: Results from the AMYPAD Diagnostic and Patient Management Study
Journal of Nuclear Medicine · 2025-01 · 66 (1) · 110-116
DOI: 10.2967/jnumed.124.268119 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 14.11.2024. Verfasst von Lyduine E Collij und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands; l.collij@amsterdamumc.nl. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Amyloid. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Several studies have demonstrated strong agreement between routine clinical visual assessment and quantification, suggesting that quantification approaches could support assessment by less experienced readers or in challenging cases. However, all studies to date have implemented a retrospective case collection, and challenging cases were generally underrepresented.
Methods
We included all participants (n = 741) from the AMYPAD diagnostic and patient management study with available baseline amyloid PET quantification. Quantification was done with the PET-only AmyPype pipeline, providing global Centiloid and regional z scores. Visual assessment was performed by local readers for the entire cohort. From the total cohort, we selected a subsample of 85 cases for which the amyloid status based on the local reader's visual assessment and the Centiloid classification (cutoff = 21) was discordant or that were assessed with low confidence (i.e., ≤3 on a 5-point scale) by the local reader. In addition, concordant negative (n = 8) and positive (n = 8) scans across tracers were selected. In this sample (n = 101 cases; [18F]flutemetamol, n = 48; [18F]florbetaben, n = 53), the visual assessments and corresponding confidence by 5 certified independent central readers were captured before and after disclosure of the quantification results.
Results
For the whole AMYPAD diagnostic and patient management study cohort, overall assessment by local readers highly agreed with Centiloid status (κ = 0.85, 92.3% agreement). This was consistently observed within disease stages (subjective cognitive decline-plus, κ = 0.82, 92.3% agreement; mild cognitive impairment, κ = 0.80, 89.8% agreement; dementia, κ = 0.87, 94.6% agreement). Across all central reader assessments in the challenging subsample, quantification of global Centiloid and regional z scores was considered supportive of visual reads in 70.3% and 49.3% of assessments, respectively. After disclosure of the quantitative results, we observed improvement in concordance across the 5 readers (baseline κ = 0.65, 65.3% agreement; κ after disclosure = 0.74, 73.3% agreement) and a significant increase in reader confidence (baseline mean (M) = 4.0 vs. M after disclosure = 4.34, Wilcoxon statistic (W) = 101,056, P < 0.001).
Conclusion
In this clinical study enriched for challenging amyloid PET cases, we demonstrate the value of quantification to support visual assessment. After disclosure, both interreader agreement and confidence showed significant improvement. These results are important considering the arrival of antiamyloid therapies, which used the Centiloid metric for trial inclusion and target engagement. Moreover, quantification could support determination of amyloid-β status with high certainty, an important factor for treatment initiation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands; l.collij@amsterdamumc.nl.
- Brain Imaging, Amsterdam Neuroscience, Amsterdam, The Netherlands.
- Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund, Sweden.
- Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- Institute of Neuroscience and Medicine, Molecular Organization of the Brain, Forschungszentrum Jülich, Jülich, Germany.
- Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Zitieren
APA
Collij, L. E., Bischof, G. N., Altomare, D., Bader, I., Battle, M., Vállez García, D., Lopes Alves, I., Wolz, R., Gismondi, R., Stephens, A., Walker, Z., Scheltens, P., Nordberg, A., Gispert, J. D., Drzezga, A., Perissinotti, A., Morbelli, S., Buckley, C., Garibotto, V., …, & AMYPAD Consortium (2025). Quantification Supports Amyloid PET Visual Assessment of Challenging Cases: Results from the AMYPAD Diagnostic and Patient Management Study. Journal of Nuclear Medicine, 66(1), 110-116. https://doi.org/10.2967/jnumed.124.268119
Vancouver
Collij LE, Bischof GN, Altomare D, Bader I, Battle M, Vállez García D, et al. Quantification Supports Amyloid PET Visual Assessment of Challenging Cases: Results from the AMYPAD Diagnostic and Patient Management Study. Journal of Nuclear Medicine. 2025;66(1):110-116. doi:10.2967/jnumed.124.268119
BibTeX
@article{Collij2025,
author = {Collij, Lyduine E and Bischof, Gérard N and Altomare, Daniele and Bader, Ilse and Battle, Mark and Vállez García, David and Lopes Alves, Isadora and Wolz, Robin and Gismondi, Rossella and Stephens, Andrew and Walker, Zuzana and Scheltens, Philip and Nordberg, Agneta and Gispert, Juan Domingo and Drzezga, Alexander and Perissinotti, Andrés and Morbelli, Silvia and Buckley, Christopher and Garibotto, Valentina and Frisoni, Giovanni B and Farrar, Gill and Barkhof, Frederik and AMYPAD Consortium, AMYPAD Consortium},
title = {Quantification Supports Amyloid PET Visual Assessment of Challenging Cases: Results from the AMYPAD Diagnostic and Patient Management Study},
journal = {Journal of Nuclear Medicine},
year = {2025},
volume = {66},
number = {1},
pages = {110--116},
doi = {10.2967/jnumed.124.268119}
}
EUVIMED